Skip to main content
SpringerLink
Log in

Endocrine Therapies in the Adjuvant and Advanced Disease Settings

  • Chapter
  • First Online:
Breast Cancer

  • 123k Accesses

Abstract

Significant improvements in the outcome of breast cancer have been achieved in the last two decades, endocrine therapy being one of the key contributors of this success.

Careful evaluation and integration of both the degree of endocrine responsiveness and disease status need to drive the therapeutic decision for the optimal endocrine strategy in the individual patient.

The chapter will focus on the indications of adjuvant and palliative endocrine treatment in pre- and postmenopausal women and discuss the most recent guidelines’ recommendations. The specific scenario of elderly patients will be addressed in a separate contribution.

The overall aim is to highlight the complexity of different disease settings and to help clinicians to understand and select the available choices when sitting in a multidisciplinary meeting or in front of the patient.

Some open topics and their related clinical and research implications will be addressed, in particular the concept and relevance of endocrine resistance, the need for reliable biomarkers of disease response, the most relevant unanswered questions, and the need for innovative clinical trial designs.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 139.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 179.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 249.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Bentzon N, Düring M, Rasmussen BB et al (2008) Prognostic effect of estrogen receptor status across age in primary breast cancer. Int J Cancer 122(5):1089–1094

    Article  CAS  PubMed  Google Scholar 

  2. Collins LC, Marotti JD, Gelber S et al (2012) Pathologic features and molecular phenotype by patient age in a large cohort of young women with breast cancer. Breast Cancer Res Treat 131(3):1061–1066

    Article  CAS  PubMed  Google Scholar 

  3. Rhodes A, Jasani B, Balaton AJ et al (2000) Frequency of oestrogen and progesterone receptor positivity by immunohistochemical analysis in 7016 breast carcinomas: correlation with patient age, assay sensitivity, threshold value, and mammographic screening. J Clin Pathol 53(9):688–696

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  4. Schonberg MA, Marcantonio ER, Li D et al (2010) Breast cancer among the oldest old: tumor characteristics, treatment choices, and survival. J Clin Oncol 28(12):2038–2045

    Article  PubMed  PubMed Central  Google Scholar 

  5. Rhodes A, Jasani B, Balaton AJ, Miller KD (2000) Immunohistochemical demonstration of oestrogen and progesterone receptors: correlation of standards achieved on in house tumours with that achieved on external quality assessment material in over 150 laboratories from 26 countries. J Clin Pathol 53(4):292–301

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  6. Hammond ME, Hayes DF, Dowsett M et al (2010) American Society of Clinical Oncology/College Of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. J Clin Oncol 28(16):2784–2795

    Article  PubMed  PubMed Central  Google Scholar 

  7. Balduzzi A, Bagnardi V, Rotmensz N et al (2014) Survival outcomes in breast cancer patients with low estrogen/progesterone receptor expression. Clin Breast Cancer 14(4):258–264

    Article  PubMed  Google Scholar 

  8. Davies C, Godwin J, Gray R et al; Early Breast Cancer Trialists’ Collaborative Group (EBCTCG) (2011) Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials. Lancet 378: 771–784

    Google Scholar 

  9. Dowsett M, Allred C, Knox J et al (2008) Relationship between quantitative estrogen and progesterone receptor expression and human epidermal growth factor receptor 2 (HER-2) status with recurrence in the Arimidex, Tamoxifen, Alone or in Combination Trial. J Clin Oncol 26:1059–1065

    Article  CAS  PubMed  Google Scholar 

  10. Regan MM, Pagani O, Francis PA et al (2015) Predictive value and clinical utility of centrally assessed ER, PgR, and Ki-67 to select adjuvant endocrine therapy for premenopausal women with hormone receptor-positive, HER2-negative early breast cancer: TEXT and SOFT trials. Breast Cancer Res Treat 154(2):275–286

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  11. Yamashita H, Yando Y, Nishio M et al (2006) Immunohistochemical evaluation of hormone receptor status for predicting response to endocrine therapy in metastatic breast cancer. Breast Cancer 13:74–83

    Article  PubMed  Google Scholar 

  12. De Vos FY, van Laarhoven HW, Laven JS et al (2012) Menopausal status and adjuvant hormonal therapy for breast cancer patients: a practical guideline. Crit Rev Oncol Hematol 84(2):252–260

    Article  PubMed  Google Scholar 

  13. Ortmann O, Pagani O, Jones A et al (2011) Which factors should be taken into account in perimenopausal women with early breast cancer who may become eligible for an aromatase inhibitor? Recommendations of an expert panel. Cancer Treat Rev 37(2):97–104

    Article  CAS  PubMed  Google Scholar 

  14. Cancello G, Maisonneuve P, Rotmensz N et al (2013) Progesterone receptor loss identifies Luminal B breast cancer subgroups at higher risk of relapse. Ann Oncol 24(3):661–668

    Article  CAS  PubMed  Google Scholar 

  15. Osborne CK, Kitten L, Arteaga CL (1989) Antagonism of chemotherapy-induced cytotoxicity for human breast cancer cells by antiestrogens. J Clin Oncol 7:710–717

    Article  CAS  PubMed  Google Scholar 

  16. Albain KS, Barlow WE, Ravdin PM et al (2009) Adjuvant chemotherapy and timing of tamoxifen in postmenopausal patients with endocrine-responsive, node-positive breast cancer: a phase 3, open-label, randomised controlled trial. Lancet 374(9707):2055–2063

    Article  PubMed  PubMed Central  Google Scholar 

  17. Bedognetti D, Sertoli MR, Pronzato P et al (2011) Concurrent vs sequential adjuvant chemotherapy and hormone therapy in breast cancer: a multicenter randomized phase III trial. J Natl Cancer Inst 103(20):1529–1539

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  18. Bartlett J, Canney P, Campbell A et al (2013) Selecting breast cancer patients for chemotherapy: the opening of the UK OPTIMA trial. Clin Oncol (R Coll Radiol) 25:109–116

    Article  CAS  Google Scholar 

  19. Ravdin RG, Lewison EF, Slack NH et al (1970) Results of a clinical trial concerning the worth of prophylactic oophorectomy for breast carcinoma. Surg Gynecol Obstet 131:1055–1064

    CAS  PubMed  Google Scholar 

  20. Early Breast Cancer Trialists’ Collaborative Group (EBCTCG) (2005) Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 365:1687–1717

    Article  Google Scholar 

  21. LHRH-agonists in Early Breast Cancer Overview group (2007) Use of luteinising-hormone-releasing hormone agonists as adjuvant treatment in premenopausal patients with hormone-receptor-positive breast cancer: a meta-analysis of individual patient data from randomised adjuvant trials. Lancet 369:1711–1723

    Article  Google Scholar 

  22. Rossi L, Pagani O (2015) Impact of breast cancer treatment on fertility. In: Biglia N, Peccatori FA (eds) Breast cancer, fertility preservation and reproduction. Springer International Publishing, Switzerland. doi:10.1007/978-3-319-17278-1_3

    Google Scholar 

  23. Hackshaw A, Baum M, Fornander T et al (2009) Long-term effectiveness of adjuvant goserelin in premenopausal women with early breast cancer. J Natl Cancer Inst 101(5):341–349

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  24. Goel S, Sharma R, Hamilton A, Beith J (2009) LHRH agonists for adjuvant therapy of early breast cancer in premenopausal women. Cochrane Database Syst Rev (4): CD004562. DOI: 10.1002/14651858.CD004562.pub4

  25. Yan S, Li K, Jiao X, Zou H (2015) Tamoxifen with ovarian function soppression versus tamoxifen alone as an adjuvant treatment for premenopausal breast cancer: a meta-analysis of published randomized controlled trials. Onco Targets Ther 8:1433–1441

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  26. Francis PA, Regan MM, Fleming GF et al (2015) Adjuvant Ovarian Suppression in Premenopausal Breast Cancer. N Engl J Med 372(5):436–446

    Article  PubMed  Google Scholar 

  27. Burstein HJ, Lacchetti C, Anderson H et al (2016) Adjuvant endocrine therapy for women with hormone receptor-positive breast cancer: American Society of Clinical Oncology Clinical Practice Guideline update on ovarian suppression. J Clin Oncol 34(14):1689–1701

    Google Scholar 

  28. Coates AS, Winer EP, Goldhirsch A et al (2015) Tailoring therapies-improving the management of early breast cancer: St Gallen International Expert Consensus on the Primary Therapy of early breast cancer. Ann Oncol 26(8):1533–1546

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  29. NCCN (2016) clinical practice guidelines in oncology. Breast cancer. Version 1.2016. Available at http://www.nccn.com

  30. Paluch-Shimon S, Pagani O, Partridge AH et al (2016) Second international consensus guidelines for breast cancer in young women (BCY2). Breast 26:87–99

    Article  PubMed  Google Scholar 

  31. Masuda N, Iwata H, Rai Y et al (2011) Monthly versus 3-monthly goserelin acetate treatment in pre-menopausal patients with estrogen receptor-positive early breast cancer. Breast Cancer Res Treat 126(2):443–451

    Article  CAS  PubMed  Google Scholar 

  32. Howell A, Dowsett M (2004) Endocrinology and hormone therapy in breast cancer: aromatase inhibitors versus antioestrogens. Breast Cancer Res 6(6):269–274

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  33. Pfeiler G, Königsberg R, Fesl C et al (2011) Impact of body mass index on the efficacy of endocrine therapy in premenopausal patients with breast cancer: an analysis of the prospective ABCSG-12 trial. J Clin Oncol 29(19):2653–2659

    Article  CAS  PubMed  Google Scholar 

  34. Sestak I, Distler W, Forbes JF et al (2010) Effect of body mass index on recurrences in tamoxifen and anastrozole treated women: an exploratory analysis from the ATAC trial. J Clin Oncol 28(21):3411–3415

    Article  CAS  PubMed  Google Scholar 

  35. Ewertz M, Gray KP, Regan MM et al (2012) Obesity and risk of recurrence or death after adjuvant endocrine therapy with letrozole or tamoxifen in the breast international group 1-98 trial. J Clin Oncol 30(32):3967–3975

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  36. Lønning PE, Haynes BP, Dowsett M (2014) Relationship of body mass index with aromatisation and plasma and tissue oestrogen levels in postmenopausal breast cancer patients treated with aromatase inhibitors. Eur J Cancer 50(6):1055–1064

    Article  PubMed  Google Scholar 

  37. Nahta R, O’Regan RM (2012) Therapeutic implications of estrogen receptor signaling in HER2-positive breast cancers. Breast Cancer Res Treat 135(1):39–48

    Article  CAS  PubMed  Google Scholar 

  38. Cuzick J, Sestak I, Baum M et al (2010) ATAC/LATTE investigators. Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 10-year analysis of the ATAC trial. Lancet Oncol 11(12):1135–1141

    Article  CAS  PubMed  Google Scholar 

  39. Regan MM, Neven P, Giobbie-Hurder A et al (2011) BIG 1-98 Collaborative Group; International Breast Cancer Study Group (IBCSG). Assessment of letrozole and tamoxifen alone and in sequence for postmenopausal women with steroid hormone receptor-positive breast cancer: the BIG 1-98 randomised clinical trial at 8.1 years median follow-up. Lancet Oncol 12:1101–1108

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  40. Dowsett M, Forbes JF, Bradley R et al; Early Breast Cancer Trialists’ Collaborative Group (EBCTCG) (2015) Aromatase inhibitors versus tamoxifen in early breast cancer: patient-level meta-analysis of the randomised trials. Lancet 386:1341–1352

    Google Scholar 

  41. Goss PE, Ingle JN, Pritchard KI et al (2013) Exemestane versus anastrozole in postmenopausal women with early breast cancer: NCIC CTG MA.27—a randomized controlled Phase III trial. J Clin Oncol 11:1398–1404

    Article  Google Scholar 

  42. Regan MM, Price KN, Giobbie-Hurder A et al; International Breast Cancer Study Group and BIG 1-98 Collaborative Group (2011) Interpreting Breast International Group (BIG) 1-98: a randomized, double-blind, phase III trial comparing letrozole and tamoxifen as adjuvant endocrine therapy for postmenopausal women with hormone receptor-positive, early breast cancer. Breast Cancer Res 13(3):209–224

    Google Scholar 

  43. Metzger Filho O, Giobbie-Hurder A, Mallon E et al (2015) Relative effectiveness of letrozole compared with tamoxifen for patients with lobular carcinoma in the BIG 1-98 trial. J Clin Oncol 33(25):2772–2779

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  44. Pagani O, Regan MM, Walley BA et al (2014) TEXT and SOFT Investigators; International Breast Cancer Study Group. Adjuvant exemestane with ovarian suppression in premenopausal breast cancer. N Engl J Med 371(2):107–118

    Article  PubMed  PubMed Central  Google Scholar 

  45. Gnant M, Mlineritsch B, Stoeger H et al; Austrian Breast and Colorectal Cancer Study Group (2015) Zoledronic acid combined with adjuvant endocrine therapy of tamoxifen versus anastrozole plus ovarian function suppression in premenopausal early breast cancer: final analysis of the Austrian Breast and Colorectal Cancer Study Group Trial 12. Ann Oncol 26(2):313–320

    Google Scholar 

  46. Jatoi I, Anderson WF, Jeong JH, Redmond CK (2011) Breast cancer adjuvant therapy: time to consider its time-dependent effects. J Clin Oncol 29(17):2301–2304

    Article  PubMed  PubMed Central  Google Scholar 

  47. Yu KD, Wu J, Shen ZZ, Shao ZM (2012) Hazard of breast cancer-specific mortality among women with estrogen receptor-positive breast cancer after five years from diagnosis: implication for extended endocrine therapy. J Clin Endocrinol Metab 97(12):E2201–E2209

    Article  CAS  PubMed  Google Scholar 

  48. Fisher B, Dignam J, Bryant J, Wolmark N (2001) Five versus more than five years of tamoxifen for lymph node-negative breast cancer: updated findings from the National Surgical Adjuvant Breast and Bowel Project B-14 randomized trial. J Natl Cancer Inst 93:684–690

    Article  CAS  PubMed  Google Scholar 

  49. Stewart HJ, Prescott RJ, Forrest AP (2001) Scottish adjuvant tamoxifen trial: a randomized study updated to 15 years. J Natl Cancer Inst 93:456–462

    Article  CAS  PubMed  Google Scholar 

  50. Davies C, Pan H, Godwin J et al (2013) Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial. Lancet 381:805–816

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  51. Gray RG, Rea D, Handley K et al (2013) aTTom: long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years in 6,953 women with early breast cancer. J Clin Oncol 31:2013. (suppl; abstr 5)

    Google Scholar 

  52. Higgins MJ, Liedke PE, Goss PE (2013) Extended adjuvant endocrine therapy in hormone dependent breast cancer: the paradigm of the NCIC-CTG MA.17/BIG 1-97 trial. Crit Rev Oncol Hematol 86:23–32

    Article  PubMed  Google Scholar 

  53. Burstein HJ, Temin S, Anderson H et al (2014) Adjuvant endocrine therapy for women with hormone receptor-positive breast cancer: American society of clinical oncology clinical practice guideline focused update. J Clin Oncol 32(21):2255–2269

    Article  PubMed  PubMed Central  Google Scholar 

  54. Goss PE, Ingle JN, Pritchard KI et al (2016) Extending Aromatase-Inhibitor Adjuvant Therapy to 10 Years. NEJM 375(3):209–219

    Google Scholar 

  55. Senkus E, Kyriakides S, Ohno S et al (2015) Primary breast cancer: ESMO clinical practice guidelines. Ann Oncol 26(suppl 5):v8–v30

    Article  PubMed  Google Scholar 

  56. Ruddy KJ, DeSantis SD, Barry W et al (2014) Extended therapy with letrozole and ovarian suppression in premenopausal patients with breast cancer after tamoxifen. Clin Breast Cancer 14(6):413–416

    Article  CAS  PubMed  Google Scholar 

  57. Cardoso F, Costa A, Senkus E et al. HYPERLINK “https://www.ncbi.nlm.nih.gov/pubmed/27927580” 3rd ESO-ESMO international consensus guidelines for Advanced Breast Cancer (ABC3). Breast. 2017;31:244–259

    Google Scholar 

  58. Vignot S, Besse B, Andre F et al (2012) Discrepancies between primary tumor and metastasis: a literature review on clinically established biomarkers. Crit Rev Oncol Hematol 84:301–313

    Article  PubMed  Google Scholar 

  59. Gluck S (2014) Extending the clinical benefit of endocrine therapy for women with hormone receptor-positive metastatic breast cancer: differentiating mechanisms of action. Clin Breast Cancer 14:75–84

    Article  CAS  PubMed  Google Scholar 

  60. Pritchard KI (2008) Combining endocrine agents with chemotherapy: which patients and what sequence? Cancer 112(3 Suppl):718–722

    Article  CAS  PubMed  Google Scholar 

  61. Ellis MJ, Llombart-Cussac A, Feltl D et al (2015) Fulvestrant 500 mg versus anastrozole 1 mg for the first-line treatment of advanced breast cancer: overall survival analysis from the phase II first study. J Clin Oncol 33(32):3781–3787

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  62. Johnston SR, Kilburn LS, Ellis P et al (2013) Fulvestrant plus anastrozole or placebo versus exemestane alone after progression on non-steroidal aromatase inhibitors in postmenopausal patients with hormone-receptor-positive locally advanced or metastatic breast cancer (SoFEA): a composite, multicentre, phase 3 randomised trial. Lancet Oncol 14(10):989–998

    Article  CAS  PubMed  Google Scholar 

  63. Mehta RS, Barlow WE, Albain KS et al (2012) Combination anastrozole and fulvestrant in metastatic breast cancer. N Engl J Med 367(5):435–444

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  64. Hertz DL, Barlow WE, Kidwell KM et al (2016) Fulvestrant decreases anastrozole drug concentrations when taken concurrently by patients with metastatic breast cancer treated on SWOG study S0226. Br J Clin Pharmacol 81(6):1134–1141. doi:10.1111/bcp.12904

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  65. Cardoso F, Costa A, Norton L et al (2012) 1st International consensus guidelines for advanced breast cancer (ABC 1). Breast 21(3):242–252

    Article  CAS  PubMed  Google Scholar 

  66. Klijn JG, Blamey RW, Boccardo F et al (2001) Combined Hormone Agents Trialists’ Group and the European Organization for Research and Treatment of Cancer. Combined tamoxifen and luteinizing hormone-releasing hormone (LHRH) agonist versus LHRH agonist alone in premenopausal advanced breast cancer: a meta-analysis of four randomized trials. J Clin Oncol 19:343–353

    Article  CAS  PubMed  Google Scholar 

  67. Di Lascio S, Pagani O (2015) New insights into endocrine therapy for young women with breast cancer. Womens Health (Lond Engl) 11(3):343–354

    Article  Google Scholar 

  68. Reinert T, Barrios CH (2015) Optimal management of hormone receptor positive metastatic breast cancer in 2016. Ther Adv Med Oncol 7(6):304–320

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  69. Hu JC, Mokbel K (2001) Does c-erbB2/HER2 overexpression predict adjuvant tamoxifen failure in patients with early breast cancer? Eur J Surg Oncol 27:335–337

    Article  CAS  PubMed  Google Scholar 

  70. Schiff R, Massarweh SA, Shou J et al (2005) Advanced concepts in estrogen receptor biology and breast cancer endocrine resistance: implicated role of growth factor signaling and estrogen receptor coregulators. Cancer Chemother Pharmacol 56(Suppl 1):10–20

    Article  PubMed  Google Scholar 

  71. Love RR, Duc NB, Havighurst TC et al (2003) Her-2/neu overexpression and response to oophorectomy plus tamoxifen adjuvant therapy in estrogen receptor-positive premenopausal women with operable breast cancer. J Clin Oncol 21:453–457

    Article  CAS  PubMed  Google Scholar 

  72. Baselga J, Campone M, Piccart M et al (2012) Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer. N Engl J Med 366(6):520–529

    Article  CAS  PubMed  Google Scholar 

  73. Bachelot T, Bourgier C, Cropet C et al (2012) Randomized phase II trial of everolimus in combination with tamoxifen in patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative metastatic breast cancer with prior exposure to aromatase inhibitors: a GINECO study. J Clin Oncol 30(22):2718–2724

    Article  CAS  PubMed  Google Scholar 

  74. Yardley DA, Noguchi S, Pritchard KI et al (2013) Everolimus plus exemestane in postmenopausal patients with HR(+) breast cancer: BOLERO-2 final progression-free survival analysis. Adv Ther 30(10):870–884

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  75. Hortobagyi GN (2015) Everolimus plus exemestane for the treatment of advanced breast cancer: a review of subanalyses from BOLERO-2. Neoplasia 17(3):279–288

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  76. Piccart M, Hortobagyi GN, Campone M et al (2014) Everolimus plus exemestane for hormone-receptor-positive, human epidermal growth factor receptor-2-negative advanced breast cancer: overall survival results from BOLERO-2. Ann Oncol 25(12):2357–2362

    Article  CAS  PubMed  Google Scholar 

  77. Bachelot T, McCool R, Duffy S et al (2014) Comparative efficacy of everolimus plus exemestane versus fulvestrant for hormone-receptor-positive advanced breast cancer following progression/recurrence after endocrine therapy: a network meta-analysis. Breast Cancer Res Treat 143(1):125–133

    Article  CAS  PubMed  Google Scholar 

  78. Wolff AC, Lazar AA, Bondarenko I et al (2013) Randomized phase III placebo-controlled trial of letrozole plus oral temsirolimus as first-line endocrine therapy in postmenopausal women with locally advanced or metastatic breast cancer. J Clin Oncol 31(2):195–202

    Article  CAS  PubMed  Google Scholar 

  79. Gradishar WJ, Bachelot TD, Saletan S et al (2013) BOLERO-4: multicenter, open-label, phase II study of everolimus plus letrozole as first-line therapy in ER+, HER2− metastatic breast cancer. Presented at The American Society of Clinical Oncology Annual Meeting, May 31–June 4 Chicago, IL. Abstract TPS661

    Google Scholar 

  80. Bachelot TD, Chabaud S, Martin AL et al (2013) UNIRAD: multicenter, double-blind, phase III study of everolimus plus ongoing adjuvant therapy in ER+, HER2-breast cancer. J Clin Oncol 31:abstract TPS653

    Article  Google Scholar 

  81. Chavez-MacGregor M, Barlow WE, Gonzalez-Angulo AM et al (2013) Phase III randomized, placebo-controlled clinical trial evaluating the use of adjuvant endocrine therapy with or without one year of everolimus in patients with high-risk, hormone receptor-(HR) positive and HER2-neu-negative breast cancer: SWOG/NSABP S1207. J Clin Oncol 31:abstract TPS657

    Article  Google Scholar 

  82. Finn RS, Crown JP, Lang I et al (2015) The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study. Lancet Oncol 16:25–35

    Article  CAS  PubMed  Google Scholar 

  83. Turner NC, Ro J, André F et al (2015) PALOMA3 Study Group. Palbociclib in hormone-receptor-positive advanced breast cancer. N Engl J Med 373(3):209–219

    Article  CAS  PubMed  Google Scholar 

  84. Hortobagyi GN, Stemmer SM, Burris HA et al (2016) Ribociclib as First-Line Therapy for HR-Positive, Advanced Breast Cancer. NEJM 375(18):1738–1748

    Google Scholar 

  85. Cristofanilli M, Valero V, Mangalik A et al (2010) Phase II, randomized trial to compare anastrozole combined with gefitinib or placebo in postmenopausal women with hormone receptor-positive metastatic breast cancer. Clin Cancer Res 16(6):1904–1914

    Article  CAS  PubMed  Google Scholar 

  86. Tryfonidis K, Basaran G, Bogaerts J et al (2016) EORTC-Breast Cancer Group. A European Organisation for Research and Treatment of Cancer randomized, double-blind, placebo-controlled, multicentre phase II trial of anastrozole in combination with gefitinib or placebo in hormone receptor-positive advanced breast cancer (NCT00066378). Eur J Cancer 53:144–154

    Article  CAS  PubMed  Google Scholar 

  87. Yamamoto-Ibusuki M, Arnedos M, André F (2015) Targeted therapies for ER+/HER2− metastatic breast cancer. BMC Med 13:137–148

    Article  PubMed  PubMed Central  Google Scholar 

  88. Jerusalem G, Bachelot T, Barrios C et al (2015) A new era of improving progression-free survival with dual blockade in postmenopausal HR(+), HER2(−) advanced breast cancer. Cancer Treat Rev 41:94–104

    Article  PubMed  Google Scholar 

  89. Henry NL (2014) Endocrine therapy toxicity: management options. Am Soc Clin Oncol Educ Book 2014:e25–e30

    Article  Google Scholar 

  90. Rosenberg SM, Stanton AL, Petrie KJ, Partridge AH (2015) Symptoms and symptom attribution among women on endocrine therapy for breast cancer. Oncologist 20(6):598–604

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  91. Hershman DL, Shao T, Kushi LH et al (2011) Early discontinuation and non-adherence to adjuvant hormonal therapy are associated with increased mortality in women with breast cancer. Breast Cancer Res Treat 126:529–537

    Article  CAS  PubMed  Google Scholar 

  92. Pagani O, Gelber S, Colleoni M et al (2013) Impact of SERM adherence on treatment effect: International Breast Cancer Study Group Trials 13-93 and 14-93. Breast Cancer Res Treat 142(2):455–459

    Article  PubMed  PubMed Central  Google Scholar 

  93. Murphy CC, Bartholomew LK, Carpentier MY et al (2012) Adherence to adjuvant hormonal therapy among breast cancer survivors in clinical practice: a systematic review. Breast Cancer Res Treat 134:459–478

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  94. Runowicz CD, Leach CR, Henry NL et al (2016) American Cancer Society/American Society of Clinical Oncology Breast Cancer survivorship care guideline. J Clin Oncol 34(6):611–635

    Article  CAS  PubMed  Google Scholar 

  95. Christinat A, Di Lascio S, Pagani O (2013) Hormonal therapies in young breast cancer patients: when, what and for how long? J Thorac Dis 5(Suppl. 1):S36–S46

    PubMed  PubMed Central  Google Scholar 

  96. Amir E, Seruga B, Niraula S et al (2011) Toxicity of adjuvant endocrine therapy in postmenopausal breast cancer patients: a systematic review and meta-analysis. J Natl Cancer Inst 103:1299–1309

    Article  CAS  PubMed  Google Scholar 

  97. Onami S, Mortimer JE, Pal SK (2010) Cognitive changes associated with endocrine therapy for breast cancer. Maturitas 67(3):209–214

    Article  PubMed  PubMed Central  Google Scholar 

  98. Ribi K, Aldridge J, Phillips KA et al (2012) Subjective cognitive complaints one year after ceasing adjuvant endocrine treatment for early-stage breast cancer. Br J Cancer 106(10):1618–1625

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  99. Bernhard J, Luo W, Ribi K et al (2015) Patient-reported outcomes with adjuvant exemestane versus tamoxifen in premenopausal women with early breast cancer undergoing ovarian suppression (TEXT and SOFT): a combined analysis of two phase 3 randomised trials. Lancet Oncol 16:848–858

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  100. Leyland-Jones B, Gray KP, Abramovitz M et al (2015) CYP19A1 polymorphisms and clinical outcomes in postmenopausal women with hormone receptor-positive breast cancer in the BIG 1-98 trial. Breast Cancer Res Treat 151(2):373–384

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  101. Rae JM, Drury S, Hayes DF et al (2012) CYP2D6 and UGT2B7 genotype and risk of recurrence in tamoxifen-treated breast cancer patients. J Natl Cancer Inst 104:452–460

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  102. Sacco K, Grech G (2015) Actionable pharmacogenetic markers for prediction and prognosis in breast cancer. EPMA J 6(1):15–20

    Article  PubMed  PubMed Central  Google Scholar 

  103. Howard-Anderson J, Ganz PA, Bower JE et al (2012) Quality of life, fertility concerns, and behavioral health outcomes in younger breast cancer survivors: a systematic review. J Natl Cancer Inst 104(5):386–405

    Article  PubMed  Google Scholar 

  104. Ruddy KJ, Gelber SI, Tamimi RM et al (2014) Prospective study of fertility concerns and preservation strategies in young women with breast cancer. J Clin Oncol 32(11):1151–1156

    Article  PubMed  PubMed Central  Google Scholar 

  105. Loren AW, Mangu PB, Nohr Beck L et al (2013) Fertility preservation for patients with cancer: American Society of Clinical Oncology clinical practice guideline update. J Clin Oncol 31:2500–2510

    Article  PubMed  PubMed Central  Google Scholar 

  106. Peccatori FA, Azim HA Jr, Orecchia R et al (2013) Cancer, pregnancy and fertility: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 24(Supplement 6):vi160–vi170

    PubMed  Google Scholar 

  107. Tomasi-Cont N, Lambertini M, Hulsbosch S et al (2014) Strategies for fertility preservation in young early breast cancer patients. Breast 23(5):503–510

    Article  PubMed  Google Scholar 

  108. Azim HA Jr, Kroman N, Paesmans M et al (2013) Prognostic impact of pregnancy after breast cancer according to estrogen receptor status: a multicenter retrospective study. J Clin Oncol 31(1):73–79

    Article  PubMed  Google Scholar 

  109. Pagani O, Azim H Jr (2012) Pregnancy after breast cancer: myths and facts. Breast Care (Basel) 7(3):210–214

    Article  Google Scholar 

  110. Cherny NI, Sullivan R, Dafni U et al (2015) A standardised, generic, validated approach to stratify the magnitude of clinical benefit that can be anticipated from anti-cancer therapies: the European Society for Medical Oncology Magnitude of Clinical Benefit Scale (ESMO-MCBS). Ann Oncol 26(8):1547–1573

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Institute of Oncology of Southern Switzerland, Breast unit of Southern Switzerland, Bellinzona, Switzerland

    Olivia Pagani

Authors
  1. Olivia Pagani
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Olivia Pagani .

Editor information

Editors and Affiliations

  1. European Institutee of Oncology, Milan, Italy

    Umberto Veronesi

  2. European Institute of Oncology, Milan, Italy

    Aron Goldhirsch

  3. European Institute of Oncology, Milan, Italy

    Paolo Veronesi

  4. San Raffaele University and Research Hospital, Milano, Italy

    Oreste Davide Gentilini

  5. European Institute of Oncology, Milan, Italy

    Maria Cristina Leonardi

Rights and permissions

Reprints and permissions

Copyright information

© 2017 Springer International Publishing AG

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Pagani, O. (2017). Endocrine Therapies in the Adjuvant and Advanced Disease Settings. In: Veronesi, U., Goldhirsch, A., Veronesi, P., Gentilini, O., Leonardi, M. (eds) Breast Cancer. Springer, Cham. https://doi.org/10.1007/978-3-319-48848-6_45

Download citation

  • DOI: https://doi.org/10.1007/978-3-319-48848-6_45

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-319-48846-2

  • Online ISBN: 978-3-319-48848-6

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation